Evidence map›Paper›PMID 40462451›Full record

ArticleStatistics in medicine2025

A Seamless Hybrid Phase II/III Design With Bayesian Interim Subgroup Selection.

Benjamin Duputel, Nigel Stallard, François Montestruc, Sarah Zohar, Moreno Ursino

Abstract read
In one paragraph

Article in Statistics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Benjamin DuputelInserm, UMRS 1346, Université Paris Cité, Inria, HeKA, Paris, France.ORCID https://orcid.org/0000-0002-9044-7433
Nigel StallardWarwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.ORCID https://orcid.org/0000-0001-7781-1512
François MontestruceXYSTAT, Malakoff, France.
Sarah ZoharInserm, UMRS 1346, Université Paris Cité, Inria, HeKA, Paris, France.ORCID https://orcid.org/0000-0002-8429-2340
Moreno UrsinoInserm, UMRS 1346, Université Paris Cité, Inria, HeKA, Paris, France.

Funding

Association Nationale de la Recherche et de la Technologie 2019/1364Medical Research Council MR/V038419/1Medical Research Council MR/W021013/1
6 · The paper itself

Abstract

Population selection is a crucial subject in clinical development nowadays as personalized medicine is growing in interest. Evolution in biomarker scanning techniques allows for the composition and detection of sub-populations of interest when analyzing new drug responses in a disease. Seamless adaptive trials could allow for subgroup analysis with the selection of the most promising population at interim analysis. We propose a hybrid Bayesian design for seamless Phase II/III trials with binary and time-to-event outcomes for the first and second phases, respectively. In this work, at interim analysis, several prior distributions, including shrinkage prior, are compared to possibly select/discard a population, and a final test using a conditional error function as a combination method testing procedure to control the frequentist type I error is used. Simulation studies showed that the logistic regression model performs better than frequentist testing for the population selection problem when the subgroup should be selected. Shrinkage prior distributions tend to be more conservative than simpler normal distributions as studies that would have ended positively are stopped at interim analysis.

Indexed as

Clinical Trials, Phase II as TopicClinical Trials, Phase III as TopicResearch DesignAdaptive Clinical Trials as TopicBayes TheoremComputer SimulationHumansLogistic ModelsPrecision Medicinebinaryhorseshoe priorlog‐rank testsurvival analysis

Identifiers

PMID40462451
PMCPMC12134527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.